A New EP300 ‐Related Syndrome With Prominent Developmental and Immune Phenotypes
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.64050 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Devi Priyanka Maripuri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Developmental Disabilities, E1A-Associated p300 Protein, Rubinstein-Taybi Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, K08 Mentored Career Development Award, National Institutes of Health.
Abstract (Originalsprache)
Rubinstein Taybi syndrome (RTS) is a disorder of chromatin remodeling and transcriptional regulation caused by heterozygous pathogenic variants in CREBBP and EP300. RTS is characterized by a distinct facial gestalt, intellectual disability, structural kidney and heart differences, feeding difficulties, and broad thumbs and great toes. Individuals with EP300 variants tend to have milder disease, but overall disease features are similar. Recently, a cohort of individuals with heterozygous variants in exons 30–31 of CREBBP and homologous regions in EP300 was described. Affected individuals presented with global developmental delay, autism, feeding difficulties, vision and hearing impairment, and microcephaly, but did not share the typical RTS facial gestalt or organ malformations, suggesting an allelic disorder. Here we present a family with mild dysmorphisms, recurrent respiratory infections, and speech delay found by exome sequencing to have a missense variant in exon 8 of EP300 in the KIX CBP coactivator domain. Follow‐up methylation testing revealed an abnormal methylation pattern overlapping with both RTS and Cornelia de Lange syndromes. We propose that missense variants in EP300 may cause a distinct neurodevelopmental syndrome with a milder phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Genetics, Cohen Children's Northwell Health, New York, New York, USA.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Medical Genetics and Metabolism, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Alanna Strong
Förderung
- NIH HHS
- K08 Mentored Career Development Award
- National Institutes of Health
Zitieren
APA
Maripuri, D. P., Gold, J., Gold, N., & Strong, A. (2025). A New EP300 ‐Related Syndrome With Prominent Developmental and Immune Phenotypes. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64050
Vancouver
Maripuri DP, Gold J, Gold N, Strong A. A New EP300 ‐Related Syndrome With Prominent Developmental and Immune Phenotypes. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.64050
BibTeX
@article{Maripuri2025,
author = {Maripuri, Devi Priyanka and Gold, Jessica and Gold, Nina and Strong, Alanna},
title = {A New EP300 ‐Related Syndrome With Prominent Developmental and Immune Phenotypes},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.64050}
}
EUVIMED